Recent studies chiefly organized by the World Health Organization (WHO) showed that typhoid vaccines prepared differently varied in protective efficacy for man (12) . Extensive laboratory assays of potency of field trial vaccines with mice varied in relative potency and in relation to human efficacy. Influencing variables were the type of vaccine (acetone-inactivated, heat-phenol-inactivated, alcohol-treated, etc.), route of immunization [intraperitoneal (ip) or subcutaneous (sc)], menstruum of challenge culture (mucin or saline), and time interval between vaccination and challenge (7 or 14 days). Pittman and Bohner (12) found that the relative potency of acetone-inactivated and heat-phenol inactivated vaccines assayed by ip vaccination and mucin challenge after a 7-day interval (IPM7), previously referred to as type N ip or sc assay, correlated well with human efficacy, whereas the relative potency assayed by sc vaccination (SCM7) did not show correlation. Melikova et al. (10) obtained similar results with use of saline suspended challenge after a 7-day interval (IPS7 versus SCS7). However, IPM7 assay did not reflect the human efficacy of alcohol-treated vaccine, and the assay after a 14-day interval (IPM14) also failed for this type of vaccine (12) . Joo et al. (7) observed a difference in relative potency of acetone-inactivated and heat-phenol-inactivated vaccines (K and L) with a 7-and 14-day interval between vaccination and challenge, whereas Pittman and Bohner found no significant difference. There continues to be lack of consensus on the type of mouse assay for potency of typhoid vaccine. 8 We are directing our studies toward finding the cause of the variable responses to different types of vaccines. Special emphasis is being placed on the influence of the Vi antigen since the most aberrant assay results have been obtained with the alcohol-treated vaccine. Felix and Pitt (3) treated Salmonella typhosa with alcohol in order to preserve Vi antigen. The early work on acetoneinactivated typhoid vaccine claimed preservation of the Vi antigen (7) . However, the field trial acetone-inactivated vaccine K induced variable Vi antibody response in rabbits (12, 14) and practically none in man (1) . There is no substantial evidence that Vi antigen alone can protect man. Further, since Vi antigen preparations from heterologous species of bacteria alone are capable of protecting mice (4, 5) TYPHOID VACCINE AND VI ANTIGEN CFW) than with the vaccine (6.5, NIH and 6.2, CFW) but the differences were not significant. These differences were not significantly different from the relative ip-sc potency of vaccine K observed by Pittman and Bohner (12) with the use of CFW mice in a larger number of tests. In spite of the difference in the Vi agglutinin response of the two mouse strains, the relative potency obtained with Vi antigen by the two routes was the same between the mouse strains and the same as observed with the vaccine. Hence, the presence of Vi agglutinins did not appear to affect the protective response. The fact that the NIH mouse injected with soluble Vi antigen produced Vi hemagglutinins, whereas the CFW mouse did not, and the fact that the NIH mouse was protected with a lower amount of vaccine or antigen than the CFW mouse indicate that the NIH mouse is a better responder. Active cutaneous anaphylaxis. NIH mice, 7 days postimmunization, displayed ACA when challenged with either vaccine 6A or Vi antigen (Table 4 ). There was no significant difference in the reactions in NIH mice vaccinated by different routes and challenged by the two antigens. There were differences in degree of reactivity between individual animals within a treatment group. In contrast, CFW mice immunized and tested in the a NIH and CFW mice were tested 7 days postimmunization. Values shown are for NIH mice and expressed for individual mice. With CFW mice, no reaction occurred. ACA reactions were rated as follows: 0 = no reaction, tr = trace reaction, + = less than 4 mm, 1+ = 4 mm, 2+ = 4-6 mm, 3+ = 6-10 mm, and 4+ = > 10 mm.
'Immunizing doses were 0.25 ml of typhoid vaccine 6A (109 organisms per ml) or 10 l,g of Vi antigen.
c Mice were challenged by intradermal injection of 0.01 ml of typhoid vaccine 6A or 2 jug of Vi antigen.
same fashion did not respond with an immediate type hypersensitivity reaction. All control sites were negative in immunized animals challenged with saline and in nonimmunized mice challenged with the test antigens.
The difference in sensitization of the mice correlated with their difference in hemagglutinin response to Vi antigen. Whether there is a direct relation remains to be determined.
DISCUSSION
In the laboratory potency assays of typhoid vaccines employed in controlled field trials, considerable variation was noted between laboratories in the relative protective ratios of vaccines K (acetone inactivated) and L (heat-phenol inactivated; 14) . Correlation with human efficacy for most typhoid vaccines was obtained when ip immunization and mucin challenge were employed, but the results by this method with alcohol-treated vaccine reflected a poorer relationship to efficacy in man (12) . As part of an attempt to identifypossible causes for these inconsistencies, the response of three strains of mice to Vi antigen was investigated.
The three strains of mice responded differently in production of Vi antibody after injection of acetone-inactivated vaccine or purified Vi antigen. However, the differences in agglutinating antibody response or ACA were not reflected by differences in protective response to challenge with S. typhosa. CFW mice, which failed to develop hemagglutinating antibody or show ACA, exhibited the lowest protective response, but the ratios of sc to ip ED5O of both vaccine and Vi antigen were the same as with NIH mice. With NIH and Balb/cAnN mice the response to ip injection was similar in antibody and protective activity but their protective responses to sc injection differed significantly. The lower response was in the Balb/cAnN mice.
In this connection, it is interesting that the different routes of immunization did not result in significant differences in Vi antibody titers after a single injection of antigen. This appears to indicate that factors other than humoral Vi antibody must be involved in the level of protection against challenge. Perhaps some type of cellular response is initiated within the peritoneal cavity to a greater extent by ip than by sc vaccination. The concept of an important cellular response is strengthened by the appearance of protection in CFW mice in the absence of demonstrable humoral antibody after immunization with purified Vi antigen.
Further strain variation was apparent from the ACA experiments in which CFW mice failed to display this phenomenon.
